Responses
Psoriatic arthritis
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study
Compose a Response to This Article
Other responses
No responses have been published for this article.